Alpine Immune Sciences

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Alpine Immune Sciences advances drug pipeline amidst financial challenges

Alpine Immune Sciences shows promise with progress on povetacicept and strategic studies for autoimmune diseases.
While facing financial challenges, the company's strong cash position and collaborations offer growth opportunities.
Effective cost management, successful clinical trials, and market expansion are crucial for Alpine's future success.

Alpine Immune Sciences reports robust 2023 performance and clinical advancements

Alpine Immune Sciences demonstrated strong financial performance and promising clinical advancements in 2023.
The company's focus on povetacicept as a disease-modifying therapy presents significant opportunities for growth.
Challenges lie in maintaining clinical momentum and managing expenses effectively to sustain progress.
Overall, Alpine's strategic initiatives position it well for continued success in the biopharmaceutical space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alpine Immune Sciences is a clinical-stage biopharmaceutical business focused on researching and developing protein-based immunotherapies to treat autoimmune and inflammatory disorders. Its strategy incorporates a patented scientific platform for transforming native immune system proteins into differentiated, multi-targeted therapies. ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will present at the following investor conferences in January 2022: H.C. Wainwright BIOCONNECT Virtual Conference Date: Monday, January 10, 2022 Time: Available on demand beginning 7:00 a.m. ET/4:00 a.m. PT Event: Company Presentati

Alpine Immune Sciences Announces Participation in January Investor Conferences

Horizon Pharma

SEATTLE & DUBLIN--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (Nasdaq: ALPN) and Horizon Therapeutics plc (Nasdaq: HZNP) today announced an exclusive license and collaboration agreement for the development and commercialization of up to four preclinical candidates generated from Alpine's unique discovery platform. The overall agreement includes licensing of a lead, potential first-in-class preclinical candidate, as well as a research collaboration to jointly generate additional novel candidat

Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces Participation in Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference

Alpine Immune Sciences Announces Participation in Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021. “We continue to make considerable progress across our portfolio and anticipate opportunities to share clinical updates for both ALPN-202 and ALPN-303 in the first half of 2022

Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting

Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting

Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alpine Immune Sciences, Inc. (ALPN) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Bioventus

I-Mab

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.

3 Small Biotech Stocks in Focus on World Arthritis Day

Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Alpine Immune Sciences, Inc. (ALPN) Surges 6.2%: Is This an Indication of Further Gains?

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase agreement for the sale of common stock and prefunded warrants, as described below, in a private placement with certain institutional and other accredited investors for gross proceeds to Alpine of approximately $91 millio

Alpine Immune Sciences Announces $91 Million Private Placement

Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q2 2021 Results - Earnings Call Transcript

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -58.62% and 9.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Alpine Immune Sciences, Inc. (ALPN) Reports Q2 Loss, Tops Revenue Estimates

Shares of Alpine Immune Sciences (NASDAQ:ALPN) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 13.21% year over year to ($0.46), which missed the estimate of ($0.40).

Alpine Immune Sciences: Q2 Earnings Insights

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences

Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences

Will Alpine Immune Sciences, Inc. (ALPN) Report Negative Q2 Earnings? What You Should Know

Merck

Alpine Immune Sciences Inc (NASDAQ: ALPN) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK).  This collaboration will evaluate the safety and efficacy of Alpine's ALPN-202 in combination with Merck's Keytruda (pembrolizumab) in patients with advanced malignancies.

Alpine Immune Sciences Initiates Trial Collaboration With Merck

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab)

Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab)

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones

Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones Achieved Under AbbVie Collaboration

Alkermes

Biogen isn't the only company whose shares should benefit from a breakthrough drug.

Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences set to join Russell 3000® Index

Alpine Immune Sciences Set to Join Russell 3000® Index

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at the 2021 ASCO Virtual Annual Meeting

Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at the 2021 ASCO Virtual Annual Meeting

Alpine Immune Sciences Inc (NASDAQ: ALPN) has presented the preclinical data from its ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting. ALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc counterparts, as well as an anti-BAFF antibody.

Alpine Immune Sciences' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting

Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer

Alpine Immune Sciences Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer

Alpine Immune Sciences is a fundamental stock that is ideal for you to build a core long-term position. The company recently released preliminary NEON-1 data for the upcoming 2021 ASCO.

News for Alpine Immune Sciences Stock (ALPN)